×
About 2,566 results

Fraudulent Coronavirus Disease 2019 (COVID-19) Products
https://www.fda.gov/consumers/health-fraud-scams/fraudulent-coronavirus-disease-2019-covid-19-products

The U.S. Food and Drug Administration is issuing warning letters to firms for selling fraudulent products with claims to prevent, treat, mitigate, diagnose or cure coronavirus disease 2019 (COVID-19). We are actively monitoring for any firms marketing products with fraudulent COVID-19 prevention and treatment claims. The FDA is exercising its authority to protect consumers from fi...

Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases
https://pubs.acs.org/doi/pdf/10.1021/acscentsci.0c00272

Since the outbreak of the novel coronavirus disease COVID-19, caused by the SARS-CoV-2 virus, this disease has spread rapidly around the globe. Considering the potential threat of a pandemic, scientists and physicians have been racing to understand this new virus and the pathophysiology of this disease to uncover possible treatment regimens and discover effective therapeutic ag...

Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31042-4/fulltext
The Lancet;

Effective antiviral therapy is important for tackling the coronavirus disease 2019 (COVID-19) pandemic. We assessed the efficacy and safety of combined interferon beta-1b, lopinavir–ritonavir, and ribavirin for treating patients with COVID-19.

COVID-19 Treatment & Vaccine Tracker
https://covid-19tracker.milkeninstitute.org/

FasterCures, a center of the Milken Institute, is currently tracking the development of treatments and vaccines for COVID-19 (coronavirus). This tracker contains an aggregation of publicly-available information from validated sources.

Clinical features and multidisciplinary treatment outcome of COVID-19 pneumonia: A report of three cases
https://www.sciencedirect.com/science/article/pii/S0929664620301443

The novel coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a pandemic threatening global public health. In the current paper, we describe our successful treatment of three COVID-19 pneumonia patients cases including severe cases and cases with mortality risk factors. One 32-year-old male COVID-19 patient w...

Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China
https://jamanetwork.com/journals/jamacardiology/fullarticle/2763524
JAMA Cardiology;

Importance Coronavirus disease 2019 (COVID-19) has resulted in considerable morbidity and mortality worldwide since December 2019. However, information on cardiac injury in patients affected by COVID-19 is limited. Objective To explore the association between cardiac injury and mortality in patients with COVID-19. Design, Setting, and Participants This cohort study was conducted...

Fact Sheet for Health Care Providers Emergency Use Authorization (EUA) of Remdesivir (GS-5734™)
https://www.fda.gov/media/137566/download

The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) to permit the emergency use of the unapproved product remdesivir for treatment of suspected or laboratory confirmed coronavirus disease 2019 (COVID-19) in adults and children hospitalized with severe disease. Severe disease is defined as patients with an oxygen saturation (SpO2) ≤ 94% ...

Abiomed Impella RP - FDA Letter of Authorization
https://www.fda.gov/media/138460/download

This letter is in response to your request that the Food and Drug Administration (FDA) issue an Emergency Use Authorization (EUA) for emergency use of the Impella RP System1 (hereafter “Impella RP”) intended to be used by healthcare providers (HCP) in the hospital setting for providing temporary right ventricular support for up to 14 days in critical care patients2 with a body surface area ...

'Proning' Is a Promising Treatment for Coronavirus—Here's How It Works
https://www.health.com/condition/infectious-diseases/coronavirus/proning-treatment-coronavirus

Multisystem Inflammatory Syndrome in Children (MIS-C) Associated with Coronavirus Disease 2019 (COVID-19)
https://emergency.cdc.gov/han/2020/han00432.asp

The Centers for Disease Control and Prevention (CDC) is providing 1) background information on several cases of a recently reported multisystem inflammatory syndrome in children (MIS-C) associated with coronavirus disease 2019 (COVID-19); and 2) a case definition for this syndrome. CDC recommends healthcare providers report any patient who meets the case definition to local, state, and t...

Gilead’s remdesivir improves recovery time of coronavirus patients in NIH trial
https://www.washingtonpost.com/business/2020/04/29/gilead-says-positive-results-coronavirus-drug-remdesivir-will-be-released-by-nih/ 
Washington Post;

Apr 29th, 2020 - The National Institute of Allergy and Infectious Diseases study is the most rigorous test to date of the potential coronavirus treatment

Corticosteroid treatment of patients with coronavirus disease 2019 (COVID-19)
https://www.mja.com.au/system/files/issues/212_09/mja250577.pdf

Lung Health & Diseases: Coronavirus Disease (COVID-19)
https://www.lung.org/lung-health-diseases/lung-disease-lookup/covid-19

COVID-19 is a lung disease caused by a novel coronavirus first detected in late 2019. COVID-19 and its symptoms can range from mild to severe. Anyone can get COVID-19, but some individuals are more at risk for severe disease than others. There is currently no specific treatment other than supportive care available. The majority of people recover from COVID-19 within a few weeks, b...

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7159299
Lancet (London, England); Huang C, Wang Y et. al.

Jan 27th, 2020 - A recent cluster of pneumonia cases in Wuhan, China, was caused by a novel betacoronavirus, the 2019 novel coronavirus (2019-nCoV). We report the epidemiological, clinical, laboratory, and radiological characteristics and treatment and clinical outcomes of these patients. All patients with suspected 2019-nCoV were admitted to a designated hospital in Wuhan. We prospectively...

Drug treatment options for the 2019-new coronavirus (2019-nCoV).
https://www.ncbi.nlm.nih.gov/pubmed/31996494
Bioscience Trends; Lu H

Jan 27th, 2020 - As of January 22, 2020, a total of 571 cases of the 2019-new coronavirus (2019-nCoV) have been reported in 25 provinces (districts and cities) in China. At present, there is no vaccine or antiviral treatment for human and animal coronavirus, so that identifying the drug treatment options as soon as possible is critical for the response to the 2019-nCoV outbreak. Thre...

Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosi...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3526251
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America; Hirsch HH, Martino R et. al.

Oct 1st, 2012 - Community-acquired respiratory virus (CARV) infections have been recognized as a significant cause of morbidity and mortality in patients with leukemia and those undergoing hematopoietic stem cell transplantation (HSCT). Progression to lower respiratory tract infection with clinical and radiological signs of pneumonia and respiratory failure appears to depend on the intrinsic virulence of the s...

China Testing HIV Drug as Treatment for New Coronavirus, AbbVie Says
https://www.medscape.com/viewarticle/924263

Jan 27th, 2020 - (Reuters) - China is testing an HIV drug as a treatment for symptoms of the new coronavirus that is rapidly spreading, said drugmaker AbbVie Inc on Sunday. China health authorities requested the drug to help with the government's efforts to address the crisis, according to Adelle Infante, a spokeswoman for North Chicago, Illinois-based AbbVie. Aluvia, which is also known as Kaletr...

Deep Vein Thrombosis in Hospitalized Patients with Coronavirus Disease 2019 (COV...
https://doi.org/10.1161/CIRCULATIONAHA.120.046702
Circulation Zhang L, Feng X et. al.

May 18th, 2020 - Background: To investigate deep vein thrombosis (DVT) in hospitalized patients with coronavirus disease 2019 (COVID-19), we performed a single institutional study to evaluate its prevalence, risk factors, prognosis, and potential thromboprophylaxis strategies in a large referral and treatment center. Methods: We studied a total of 143 patients with COVID-19 from January 29 to Febr...

Safety and tolerability of a novel, polyclonal human anti-MERS coronavirus antib...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5871563
The Lancet. Infectious Diseases; Beigel JH, Voell J et. al.

Jan 13th, 2018 - Middle East respiratory syndrome (MERS) is a severe respiratory illness with an overall mortality of 35%. There is no licensed or proven treatment. Passive immunotherapy approaches are being developed to prevent and treat several human medical conditions where alternative therapeutic options are absent. We report the safety of a fully human polyclonal IgG antibody (SAB-301) produced from...

A Systematic Review of therapeutic agents for the treatment of the Middle East R...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7110863
Travel Medicine and Infectious Disease; Momattin H, Al-Ali AY et. al.

Jun 29th, 2019 - The Middle East Respiratory Syndrome Coronavirus (MERS-CoV) was first described in 2012 and attracted a great international attention due to multiple healthcare associated outbreaks. The disease carries a high case fatality rate of 34.5%, and there is no internationally or nationally recommended therapy. We searched MEDLINE, Science Direct, Embase and Scopus databases for relevant papers...